129 related articles for article (PubMed ID: 9208849)
1. Regulation of the oncogenic activity of BCR-ABL by a tightly bound substrate protein RIN1.
Afar DE; Han L; McLaughlin J; Wong S; Dhaka A; Parmar K; Rosenberg N; Witte ON; Colicelli J
Immunity; 1997 Jun; 6(6):773-82. PubMed ID: 9208849
[TBL] [Abstract][Full Text] [Related]
2. Mutant forms of growth factor-binding protein-2 reverse BCR-ABL-induced transformation.
Gishizky ML; Cortez D; Pendergast AM
Proc Natl Acad Sci U S A; 1995 Nov; 92(24):10889-93. PubMed ID: 7479904
[TBL] [Abstract][Full Text] [Related]
3. Tyrosine phosphorylation of p120cbl in BCR/abl transformed hematopoietic cells mediates enhanced association with phosphatidylinositol 3-kinase.
Jain SK; Langdon WY; Varticovski L
Oncogene; 1997 May; 14(18):2217-28. PubMed ID: 9174058
[TBL] [Abstract][Full Text] [Related]
4. Tyrosine phosphorylation of Grb2 by Bcr/Abl and epidermal growth factor receptor: a novel regulatory mechanism for tyrosine kinase signaling.
Li S; Couvillon AD; Brasher BB; Van Etten RA
EMBO J; 2001 Dec; 20(23):6793-804. PubMed ID: 11726515
[TBL] [Abstract][Full Text] [Related]
5. Association of phosphatidylinositol 3-kinase with SHC in chronic myelogeneous leukemia cells.
Harrison-Findik D; Susa M; Varticovski L
Oncogene; 1995 Apr; 10(7):1385-91. PubMed ID: 7537361
[TBL] [Abstract][Full Text] [Related]
6. Bcr-Abl oncoproteins bind directly to activators of the Ras signalling pathway.
Puil L; Liu J; Gish G; Mbamalu G; Bowtell D; Pelicci PG; Arlinghaus R; Pawson T
EMBO J; 1994 Feb; 13(4):764-73. PubMed ID: 8112292
[TBL] [Abstract][Full Text] [Related]
7. ABL fusion oncogene transformation and inhibitor sensitivity are mediated by the cellular regulator RIN1.
Thai M; Ting PY; McLaughlin J; Cheng D; Müschen M; Witte ON; Colicelli J
Leukemia; 2011 Feb; 25(2):290-300. PubMed ID: 21102429
[TBL] [Abstract][Full Text] [Related]
8. The SH2-containing adapter protein GRB10 interacts with BCR-ABL.
Bai RY; Jahn T; Schrem S; Munzert G; Weidner KM; Wang JY; Duyster J
Oncogene; 1998 Aug; 17(8):941-8. PubMed ID: 9747873
[TBL] [Abstract][Full Text] [Related]
9. Phosphatidylinositol 3-kinase p85{alpha} subunit-dependent interaction with BCR/ABL-related fusion tyrosine kinases: molecular mechanisms and biological consequences.
Ren SY; Bolton E; Mohi MG; Morrione A; Neel BG; Skorski T
Mol Cell Biol; 2005 Sep; 25(18):8001-8. PubMed ID: 16135792
[TBL] [Abstract][Full Text] [Related]
10. Gads is a novel SH2 and SH3 domain-containing adaptor protein that binds to tyrosine-phosphorylated Shc.
Liu SK; McGlade CJ
Oncogene; 1998 Dec; 17(24):3073-82. PubMed ID: 9872323
[TBL] [Abstract][Full Text] [Related]
11. Coexistence of phosphotyrosine-dependent and -independent interactions between Cbl and Bcr-Abl.
Gaston I; Johnson KJ; Oda T; Bhat A; Reis M; Langdon W; Shen L; Deininger MW; Druker BJ
Exp Hematol; 2004 Jan; 32(1):113-21. PubMed ID: 14725908
[TBL] [Abstract][Full Text] [Related]
12. Structural and signaling requirements for BCR-ABL-mediated transformation and inhibition of apoptosis.
Cortez D; Kadlec L; Pendergast AM
Mol Cell Biol; 1995 Oct; 15(10):5531-41. PubMed ID: 7565705
[TBL] [Abstract][Full Text] [Related]
13. BCR-ABL-induced oncogenesis is mediated by direct interaction with the SH2 domain of the GRB-2 adaptor protein.
Pendergast AM; Quilliam LA; Cripe LD; Bassing CH; Dai Z; Li N; Batzer A; Rabun KM; Der CJ; Schlessinger J
Cell; 1993 Oct; 75(1):175-85. PubMed ID: 8402896
[TBL] [Abstract][Full Text] [Related]
14. ABL SH3 mutant inhibits BCR-ABL activity and increases imatinib sensitivity by targeting RIN1 protein in CML cell.
Liu X; Li Y; Wen L; Tao K; Xiao Q; Cao W; Huang Z; Gao M; Li H; Wang F; Feng W
Cancer Lett; 2015 Dec; 369(1):222-8. PubMed ID: 26321052
[TBL] [Abstract][Full Text] [Related]
15. Deletion of the ABL SH3 domain reactivates de-oligomerized BCR-ABL for growth factor independence.
Maru Y; Witte ON; Shibuya M
FEBS Lett; 1996 Feb; 379(3):244-6. PubMed ID: 8603698
[TBL] [Abstract][Full Text] [Related]
16. The tetramerization domain-independent Ras activation by BCR-ABL oncoprotein in hematopoietic cells.
Tauchi T; Okabe S; Miyazawa K; Ohyashiki K
Int J Oncol; 1998 Jun; 12(6):1269-76. PubMed ID: 9592185
[TBL] [Abstract][Full Text] [Related]
17. Crkl is complexed with tyrosine-phosphorylated Cbl in Ph-positive leukemia.
de Jong R; ten Hoeve J; Heisterkamp N; Groffen J
J Biol Chem; 1995 Sep; 270(37):21468-71. PubMed ID: 7545163
[TBL] [Abstract][Full Text] [Related]
18. RIN1 is an ABL tyrosine kinase activator and a regulator of epithelial-cell adhesion and migration.
Hu H; Bliss JM; Wang Y; Colicelli J
Curr Biol; 2005 May; 15(9):815-23. PubMed ID: 15886098
[TBL] [Abstract][Full Text] [Related]
19. Enhancement of ABL kinase catalytic efficiency by a direct binding regulator is independent of other regulatory mechanisms.
Cao X; Tanis KQ; Koleske AJ; Colicelli J
J Biol Chem; 2008 Nov; 283(46):31401-7. PubMed ID: 18796434
[TBL] [Abstract][Full Text] [Related]
20. Coupling between p210bcr-abl and Shc and Grb2 adaptor proteins in hematopoietic cells permits growth factor receptor-independent link to ras activation pathway.
Tauchi T; Boswell HS; Leibowitz D; Broxmeyer HE
J Exp Med; 1994 Jan; 179(1):167-75. PubMed ID: 7505797
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
